scFv(TACSTD2)-41BB-CD3zeta CAR-T Lentivirus

The scFv(TACSTD2)-41BB-CD3zeta CAR-T Lentivirus is a high-titer, replication-incompetent viral vector designed for the stable expression of a second-generation chimeric antigen receptor (CAR) in human primary T cells. The CAR construct targets Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), also designated as Trop-2, a cell surface glycoprotein frequently upregulated in epithelial carcinomas. The molecular architecture includes a Trop-2-specific single-chain variable fragment (scFv) fused to a CD8-derived hinge and transmembrane region, followed by a 4-1BB (CD137) intracellular costimulatory domain and a CD3zeta (CD3ζ) signaling moiety. This configuration is optimized to trigger potent T cell activation upon antigen recognition while promoting metabolic fitness and prolonged cellular persistence. The lentiviral delivery mechanism allows for efficient transduction and genomic integration, ensuring the progeny of the transduced T cells maintain CAR expression throughout their functional lifespan.

In experimental oncology, this lentivirus is a fundamental reagent for developing and validating Trop-2-directed adoptive immunotherapies. It is extensively used to produce CAR-T cells for functional characterization, including cytotoxicity assays against Trop-2-positive cell lines and the quantification of pro-inflammatory cytokine release, such as IFN-γ and TNF-α. Beyond initial screening, the product is essential for establishing preclinical efficacy in tumor-bearing animal models, where the 4-1BB costimulatory signaling is specifically evaluated for its ability to sustain anti-tumor responses in the immunosuppressive tumor microenvironment. Researchers leverage this vector to investigate the impact of CAR-T cell infusion on solid tumor regression and to benchmark therapeutic performance against alternative CAR architectures. It also facilitates studies on the synergy between Trop-2 CAR-T cells and other therapeutic modalities, including monoclonal antibodies or pharmacological inhibitors, to overcome antigen heterogeneity and tumor escape mechanisms.